Abstract
The N-terminal ankyrin repeat domain of the 2-5-linked oligoadenylate (2-5A)-dependent endoribonuclease, RNase L, has been crystallized by the hanging-drop vapor diffusion method in the presence of 2-5A. The crystals belong to an orthorhombic space group P212121 with cell dimensions of a = 63.11 Å, b = 73.03 Å, and c = 82.64 Å. There is one molecule per asymmetric unit. The crystals diffract to at least 2.1 Åresolution using synchrotron radiation and are suitable for X-ray structure analysis at high resolution.
Keywords: ankyrin repeat, a system, interferon, ribonuclease l
Protein & Peptide Letters
Title: Crystallization of the N-Terminal Ankyrin Repeat Domain of the 2-5ADependent Endoribonuclease, RNase L
Volume: 12 Issue: 4
Author(s): Nobutada Tanaka, Masayuki Nakanishi, Yoshio Kusakabe, Yoshikuni Goto, Yukio Kitade and Kazuo T. Nakamura
Affiliation:
Keywords: ankyrin repeat, a system, interferon, ribonuclease l
Abstract: The N-terminal ankyrin repeat domain of the 2-5-linked oligoadenylate (2-5A)-dependent endoribonuclease, RNase L, has been crystallized by the hanging-drop vapor diffusion method in the presence of 2-5A. The crystals belong to an orthorhombic space group P212121 with cell dimensions of a = 63.11 Å, b = 73.03 Å, and c = 82.64 Å. There is one molecule per asymmetric unit. The crystals diffract to at least 2.1 Åresolution using synchrotron radiation and are suitable for X-ray structure analysis at high resolution.
Export Options
About this article
Cite this article as:
Tanaka Nobutada, Nakanishi Masayuki, Kusakabe Yoshio, Goto Yoshikuni, Kitade Yukio and Nakamura T. Kazuo, Crystallization of the N-Terminal Ankyrin Repeat Domain of the 2-5ADependent Endoribonuclease, RNase L, Protein & Peptide Letters 2005; 12 (4) . https://dx.doi.org/10.2174/0929866053765734
DOI https://dx.doi.org/10.2174/0929866053765734 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Pre-eclampsia Versus Cardiovascular Disease Versus CRP
Current Hypertension Reviews Decrease in Secondary Neck Vessels in Multiple Sclerosis: A 5-year Longitudinal Magnetic Resonance Angiography Study
Current Neurovascular Research The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Current Pharmaceutical Design Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design A Review on the Current Methods of Chinese Hamster Ovary (CHO) Cells Cultivation for the Production of Therapeutic Protein
Current Drug Discovery Technologies Vaccines and Vaccine Strategies Against HIV
Current Drug Targets Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets Mucosal Immunisation: Adjuvants and Delivery Systems
Current Drug Delivery Immunomodulatory Properties of ES-62, a Phosphorylcholine - Containing Glycoprotein Secreted by Acanthocheilonema viteae
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets The Effect of Cyclosporine A on Dermal Fibroblast Cell - Transcriptomic Analysis of Inflammatory Response Pathway
Current Pharmaceutical Biotechnology Experimental and Clinical Advances in Immunotherapy Strategies for Spinal Cord Injury Target on MAIs and Their Receptors
Current Pharmaceutical Design ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis
Current Bioactive Compounds Recent Advances in Particulate-induced Pulmonary Fibrosis For the Application of Possible Strategy Experimentally and Clinically
Current Drug Targets Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Microdialysis in Drug Discovery
Current Drug Discovery Technologies